Dexcom
Dexcom G7

Dexcom G7

The most accurate CGM. Period. 1-3
For better patient diabetes management after hospital discharge. 4

We want to hear from you. Email us at HospitalDischarge@Dexcom.com so we can get in touch with more details, or scroll down to learn more.

Patients using Dexcom CGM resulted in

dexcom g7

reduced diabetes-related inpatient admission costs5

dexcom g7

reduced diabetes-related inpatient visits6

Diabetes increases the risk of a 30-day hospital readmission by up to 2.5 times.7-9
Hospital discharge is an opportunity to initiate Dexcom G7 for diabetes management.

Dexcom g7 patient

Empower your patients to take control of their health

The Dexcom hospital discharge program provides a Dexcom G7 Continuous Glucose Monitoring (CGM) System to any patient who is discharged from the hospital and has been identified as an appropriate candidate for CGM. By using Dexcom G7, patients will be able to see their glucose in real time and how fast it’s changing. They can also see how food and activity affect their glucose.

The most accurate CGM. Period.1-3

Dexcom G7 improves outcomes for people living with diabetes,10-14 including type 1 or type 2 and those who are pregnant, through its features designed to support exceptional results.

Significant decline in rebound hyperglycemia

Significant decline in rebound hyperglycemia15

The only iCGM with an Urgent Low Soon alert that can notify you of a low 20 minutes before it happens

72% reduction in hypoglycemia

72% reduction in hypoglycemia16

Delayed onset hyperglycemia alarm, customizable High/Low Alerts, and Urgent Low Soon alert

Increases time in range

Increases time in range

Proven to increase time in range by reducing hyper- and hypoglycemia10-14

No fingersticks

No fingersticks

The only CGM that offers no fingersticks from day 1*

*Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Urgent Low Soon alert and Delay 1st alert

Urgent Low Soon alert and Delay 1st alert

The only CGM system with the Urgent Low Soon alert and the Delay 1st alert that helps protect from severe hypoglycemia and diabetic ketoacidosis

The most connected CGM

The most connected CGM17

Dexcom G7 connects to more apps, insulin pumps, and technology than any other brand

Designed for simplicity,
easy to get started

The Dexcom G7 program includes everything patients need to get started so they can quickly be on their way to easier diabetes management.


The trial kit includes:
Applicator
Simple sensor insertion at the push of a button

All-in-one sensor
Measures glucose levels through a small wire inserted just underneath the skin

Instructions
Dexcom G7 set-up guide, instructions for use, and an activation card to get patients started


Patients who want to continue on Dexcom G7 will need a prescription. To ensure there is no lapse in use, it is recommended that a prescription be provided at discharge with the instruction to obtain their first Dexcom G7 CGM System at the hospital pharmacy.
dexcom g7
98% of patients have coverage for Dexcom G7

Get your hospital started with the Dexcom G7 discharge program

Email us at HospitalDischarge@Dexcom.com, or click below to send an email to a Dexcom representative who will reach out to share the benefits of bringing this program to your organization. Please be sure to include any helpful info, such as your full name, title, hospital/organization name, and location.


†Compatible smart device must be provided by patient.
1 Dexcom, Data on File, 2023. 2 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. https://www.accessdata.fda.gov/cdrh_docs/reviews/K213919.pdf. 3 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. https://www.accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf. 4 Galindo, RJ. et al. Diabetes 2021; 70 (Supp 1): 613–P. 5 Norman GJ, et al. Diabetes Technol Ther. 2022;24(7):520-524. 6 Hannah K, et al. Diabetes. 2023;72(Suppl 1):991-P. 7 Enomoto LM, et al. J Diabetes Complicat. 2017;31(1):122-127. 8 Sonmez H et al. J Diabetes Complicat. 2017;31(12):1681-1685. 9 Ostling S et al. Clin Diab Endocrinol. 2017:3(1):1-8. 10 Beck RW, et al. JAMA. 2017;317(4):371-378. 11 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 12 Martens T, et al. JAMA. 2021;325(22):2262-2272. 13 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 14 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 15 Acciaroli G, et al. J Diabetes Sci Technol. 2022;16(3):677-682. 16 Heinemann L, et al. Lancet. 2018;391(10128):1367-1378. 17 Dexcom, Data on File, 2024.

BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.